As KRT19 represents the extent of the EGFR wt component in lung tumor, EGFR-TKI's efficacy in NSCLC is poor in high serum KRT19 group compared with normal serum KRT19 group. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.